Cerus CE marks Intercept for frozen plasma
This article was originally published in Clinica
Concord, California company Cerus has CE marked its Intercept blood system, allowing its sale in Europe to purify previously frozen plasma. Intercept is designed to reduce the risk of diseases being transmitted in contaminated blood by inactivating a broad range of viral, bacterial and parasitic pathogens, as well as harmful white blood cells that may be present in donated blood. The expanded claim means that blood banks in countries that recognise the CE mark may now use Intercept to purify either previously frozen or freshly collected plasma. This will help to permit the use of imported plasma and plasma in quarantined inventory, both of which are previously frozen. Cerus CE marked the Intercept system for platelets in 2002 and for fresh plasma in 2006 (see Clinica No 1236, p 22).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.